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Summary
Background Incorporation of a taxane as adjuvant treatment for early breast cancer oﬀ ers potential for further 
improvement of anthracycline-based treatment. The UK TACT study (CRUK01/001) investigated whether sequential 
docetaxel after anthracycline chemotherapy would improve patient outcome compared with standard chemotherapy 
of similar duration. 
Methods In this multicentre, open-label, phase III, randomised controlled trial, 4162 women (aged >18 years) with 
node-positive or high-risk node-negative operable early breast cancer were randomly assigned by computer-generated 
permuted block randomisation to receive FEC (ﬂ uorouracil 600 mg/m², epirubicin 60 mg/m², cyclophosphamide 
600 mg/m² at 3-weekly intervals) for four cycles followed by docetaxel (100 mg/m² at 3-weekly intervals) for four cycles 
(n=2073) or control (n=2089). For the control regimen, centres chose either FEC for eight cycles (n=1265) or epirubicin 
(100 mg/m² at 3-weekly intervals) for four cycles followed by CMF (cyclophosphamide 600 mg/m², methotrexate 
40 mg/m², and ﬂ uorouracil 600 mg/m² at 4-weekly intervals) for four cycles (n=824). The primary endpoint was 
disease-free survival. Analysis was by intention to treat (ITT). This study is registered as an International Standard 
Randomised Controlled Trial, number ISRCTN79718493.
Findings All randomised patients were included in the ITT population. With a median follow-up of 62 months, 
disease-free survival events were seen in 517 of 2073 patients in the experimental group compared with 539 of 
2089 controls (hazard ratio [HR] 0·95, 95% CI 0·85–1·08; p=0·44). 75·6% (95% CI 73·7–77·5) of patients in the 
experimental group and 74·3% (72·3–76·2) of controls were alive and disease-free at 5 years. The proportion of 
patients who reported any acute grade 3 or 4 adverse event was signiﬁ cantly greater in the experimental group than in 
the control group (p<0·0001); the most frequent events were neutropenia (937 events vs 797 events), leucopenia 
(507 vs 362), and lethargy (456 vs 272). 
Interpretation This study did not show any overall gain from the addition of docetaxel to standard anthracycline 
chemotherapy. Exploration of predictive biomarker-deﬁ ned subgroups might have the potential to better target the 
use of taxane-based therapy. 
Funding Cancer Research UK (CRUK 01/001), Sanoﬁ -Aventis, Pﬁ zer, and Roche.
Introduction 
Adjuvant chemotherapy has improved survival for 
women with early breast cancer over the past 30 years. 
During the 1990s, anthracycline chemotherapy was 
shown to be superior to CMF (cyclophosphamide, 
methotrexate, and ﬂ uorouracil).1,2 Incorporation of a 
taxane (paclitaxel or docetaxel) oﬀ ered potential for 
further improvement of patient outcomes.
Initial reports from two trials of adjuvant taxanes were 
presented at the 2000 National Institutes of Health (NIH) 
Consensus Development Conference (Bethesda MD, 
USA). In these trials, four cycles of paclitaxel were added 
to four cycles of doxorubicin plus cyclophosphamide. 
Results from the CALBG 9344 trial showed a modest 
disease-free survival beneﬁ t for paclitaxel compared with 
control; the NSABP B-28 study showed no signiﬁ cant 
diﬀ erence, although follow-up at that time was short 
(both trials have subsequently published results3,4). The 
NIH Consensus Panel concluded that there was 
insuﬃ  cient evidence to support routine use of taxanes in 
early breast cancer and called for carefully designed 
studies to be undertaken, particularly trials that compared 
the incorporation of taxanes as adjuvant therapy with 
anthracycline treatment of similar duration.
TACT (Taxotere as Adjuvant Chemotherapy Trial) was 
developed in 2000 to investigate whether sequential 
doce taxel (Taxotere, Sanoﬁ -Aventis, Bridgewater, NJ, 
USA) given at 3-weekly intervals after anthracycline 
chemo therapy would improve patient outcome com-
pared with standard anthracycline chemotherapy of 
similar dura tion. With over 4000 patients, the study was 
powered to detect small but clinically worthwhile 
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beneﬁ ts in dis ease-free survival, to assess quality of life 
and, with a parallel translational research programme, 
to identify sub groups in which docetaxel might have 
speciﬁ c beneﬁ t. 
Methods
Patients
This multicentre, phase III, randomised controlled trial 
was undertaken in 103 centres in the UK and one centre 
in Belgium (including specialist cancer hospitals, 
university teaching hospitals, and smaller community 
general hospitals). Patients eligible for the trial were 
women aged more than 18 years with operable invasive 
breast cancer (International Union Against Cancer 
Figure 1: Trial proﬁ le
CMF=cyclophosphamide, methotrexate, and ﬂ uorouracil. DCIS=ductal carcinoma in situ. E-CMF=epirubicin 
followed by CMF. FEC=ﬂ uorouracil, epirubicin, and cyclophosphamide. FEC-D=FEC followed by docetaxel. Numbers 
of patients screened and assessed for eligibility were not routinely collected.
Eﬃcacy analysis population
Safety analysis population
4162 patients randomised
2089 assigned to control
1265 from centres using FEC control
824 from centres using E-CMF control
15 not eligible
9 unevaluable
6 metastatic disease
1 bilateral cancer
1 previous breast cancer
1 synchronous ovarian cancer
6 other protocol violation
2 abnormal liver function
2 reduced cardiac function
1 poor wound healing
1 incomplete excision
15 did not start allocated treatment
6 ineligible (unevaluable)
5 ineligible (protocol violation)
1 received FEC-D in error
3 patient choice
2074 received allocated treatment
Followed up
2089 randomised
378 (18%) died
1608 (77%) complete follow-up
65 (3%) >15 months since last seen
38 (2%) withdrawn or lost to follow-up
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15 not eligible
7 unevaluable
5 metastatic disease
1 bilateral cancer
1 DCIS only
8 other protocol violation
2 abnormal liver function
1 reduced cardiac function
3 poor wound healing
1 incomplete excision
1 leucopenia
Followed up
2073 randomised
374 (18%) died
1583 (76%) complete follow-up
87 (4%) >15 months since last seen
29 (1%) withdrawn or lost to follow-up
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Toxicity/illness
Patient choice
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Progression/died
Other
2061 received allocated treatment
12 did not start allocated treatment
4 ineligible (unevaluable)
4 ineligible (protocol violation)
3 received E-CMF in error
1 patient choice
2073 assigned to FEC-D
1258 from centres using FEC control
815 from centres using E-CMF control
FEC-D (experimental) 
group (n=2073)
Control group 
(n=2089)
Age (years) 48·9 (8·6) 48·4 (8·5)
Age-group (years)
<40 346 (16·7%) 373 (17·9%)
40–49 753 (36·3%) 813 (38·9%)
50–59 772 (37·2%) 714 (34·2%)
≥60 202 (9·7%) 189 (9·0%)
Type of surgery and radiotherapy use
Mastectomy 1150 (55·5%) 1116 (53·4%)
With radiotherapy 929 (80·8%) 885 (79·3%)
Wide local excision 923 (44·5%) 973 (46·6%)
With radiotherapy 895 (97·0%) 943 (96·9%)
Nodal status
Node negative 419 (20·2%) 416 (19·9%)
1–3 positive nodes 917 (44·2%) 922 (44·1%)
≥4 positive nodes 737 (35·6%) 751 (36·0%)
Tumour grade*
Grade 1 117 (5·7%) 112 (5·4%)
Grade 2 763 (37·0%) 773 (37·1%)
Grade 3 1182 (57·3%) 1200 (57·6%)
Tumour size†
<2 cm 696 (33·6%) 739 (35·4%)
2–5 cm 1164 (56·2%) 1166 (55·9%)
>5 cm 211 (10·2%) 181 (8·7%)
ER status
Positive 1438 (69·4%) 1438 (68·8%)
Negative 635 (30·6%) 651 (31·2%)
HER2 status‡
Positive 420 (23·8%) 427 (23·7%)
Negative 1347 (76·2%) 1377 (76·3%)
Endocrine treatment in ER-positive patients§
Tamoxifen monotherapy 929 (64·6%) 862 (59·9%)
Tamoxifen followed by 
aromatase inhibitor
426 (29·6%) 467 (32·5%)
Aromatase inhibitor 
monotherapy
55 (3·8%) 82 (5·7%)
No endocrine treatment/
unknown
28 (1·9%) 27 (1·9%)
Trastuzumab in HER2-positive patients¶
Yes 38 (9·0%) 36 (8·4%)
No 312 (74·3%) 313 (73·3%)
Not known 70 (16·7%) 78 (18·3%)
Data are n (%) or mean (SD). ER=oestrogen receptor. FEC-D=ﬂ uorouracil, 
epirubicin, and cyclophosphamide followed by docetaxel. HER2=human 
epidermal growth factor receptor 2. *FEC-D group, n=2062; control group, 
n=2085. †FEC-D group, n=2071; control group, n=2086. ‡FEC-D group, n=1767; 
control group, n=1804. §FEC-D group, n=1438; control group, n=1438. ¶FEC-D 
group, n=420; control group, n=427.
Table 1: Baseline characteristics and details of other adjuvant treatment 
by randomised treatment group
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stage pT1-3a pN0-1 M0) who had undergone complete 
excision and were to be treated with adjuvant 
chemotherapy—ie, those with node- positive or high-risk 
node- negative disease (eg, grade 3, hormone - receptor-
 negative, or lympho vascular invasion). Additionally, 
patients needed to have normal haematological, hepatic, 
and renal function. Exclusion criteria included locally 
advanced or distant disease, bilateral breast cancer, 
pregnancy, and previous invasive malignancy within 
10 years. Deter mination of oestrogen receptor (ER) was 
mandatory and randomisation was within 8 weeks of 
deﬁ nitive surgery. Representative tumour blocks were 
requested prospectively for human epidermal growth 
factor receptor-2 (HER2) testing at central reference 
laboratories.5 Tissue from consenting patients was 
stored in microarrays for further translational 
research.
TACT (CRUK01/001) was approved by the national 
South East Multi-Research Ethics Committee (MREC 
00/1/59) and the local ethics committees of all 
participating centres. All enrolled patients provided 
written informed consent. The Clinical Trials and 
Statistics Unit at the Institute of Cancer Research (Sutton, 
UK; ICR-CTSU) had overall responsibility for trial 
coordination with four collaborating clinical trials units 
responsible for regional data management and 
randomisation. The Trial Management Group was 
responsible for the day-to-day running of the trial. The 
trial was overseen by an Independent Trial Steering 
Committee. Emerging safety and eﬃ  cacy data were 
reviewed regularly in conﬁ dence by the Independent 
Data Monitoring Committee. Data were collated at 
regular intervals at ICR-CTSU where all interim and ﬁ nal 
analyses were done. Central statistical monitoring was 
done by ICR-CTSU and was supplemented by selected 
on-site source document veriﬁ cation.
Randomisation
Patients were randomised in a 1:1 ratio to an experimental 
taxane regimen or control. Before activating the trial, 
centres declared which of two UK standard anthracycline 
regimens would be used as control. Independent 
randomisation was by telephone to the ICR-CTSU or one 
of four regional clinical trial units. Computer-generated 
permuted blocks were used; stratiﬁ cation was by centre, 
nodal status (none, one to three, or four or more), and ER 
status. This trial was open label.
Procedures 
Control regimens were FEC (ﬂ uorouracil 600 mg/m², 
epirubicin 60 mg/m², and cyclophosphamide 600 mg/m², 
all intravenously on day 1 every 21 days) for eight cycles or 
epirubicin (100 mg/m² intravenously on day 1 every 
21 days) for four cycles followed by CMF (cyclo-
phosphamide 600 mg/m², methotrexate 40 mg/m², and 
ﬂ uorouracil 600 mg/m², all intravenously on days 1 and 8 
every 28 days; E-CMF) for four cycles. Centres could 
FEC-D (experimental) 
group (n=2073)
Control group (n=2089) Total (N=4162)
n (%) Cumulative 
proportion 
(%)
n (%) Cumulative 
proportion (%)
n (%) Cumulative 
proportion 
(%)
Number of cycles received
0 12 (0·6%) 0·6% 15 (0·7%) 0·7% 27 (0·7%) 0·7% 
1 9 (0·4%) 1·0% 8 (0·4%) 1·1% 17 (0·4%) 1·1%
2 5 (0·2%) 1·3% 9 (0·4%) 1·5% 14 (0·3%) 1·4%
3 7 (0·3%) 1·6% 10 (0·5%) 2·0% 17 (0·4%) 1·8%
4 107 (5·2%) 6·8% 12 (0·6%) 2·6% 119 (2·9%) 4·7%
5 115 (5·6%) 12·3% 30 (1·4%) 4·0% 145 (3·5%) 8·2%
6 73 (3·5%) 15·8% 243 (11·6%) 15·7% 316 (7·6%) 15·7%
7 74 (3·6%) 19·4% 76 (3·6%) 19·3% 150 (3·6%) 19·3%
8 1671 (80·6%) 100·0% 1686 (80·7%) 100·0% 3357 (80·7%) 100·0%
Relative dose intensity* >85%
Overall 1595 (77·3%) ·· 1614 (77·4%) ·· 3209 (77·3%) ··
Cycles 1–4 1844 (89·3%) ·· 1891 (90·7%) ·· 3735 (90·0%) ··
Cycles 5–8† 1375 (66·6%) ·· 1500 (71·9%) ·· 2875 (69·3%) ··
FEC-D=ﬂ uorouracil, epirubicin, and cyclophosphamide followed by docetaxel. *Per patient relative dose intensity was 
calculated as a mean of the cycle-speciﬁ c relative dose intensities over the planned number of cycles. 12 treated 
patients with no information on dose or dates of cycles are excluded (ie, FEC-D, n=2064; control, n=2086; total, 
n=4150). †χ2 (1 df)=13·6, p=0·0002 for control versus FEC-D.
Table 2: Compliance with randomised treatment
FEC-D 
(experimental) 
group 
(n=2073)
Control 
group 
(n=2089)
Number of patients with event contributing 
to disease-free survival analysis
517 539
Local recurrence 74 105
Distant recurrence 382 378
New breast disease* 32 34
Death from other cause (no recurrence) 29 22
Distant relapse ever reported† 446 465
New breast disease ever reported* 45 47
All non-breast cancer second primary 
tumours
44 41
Gastrointestinal 11 12
Gynaecological 9 10
Skin 10 6
Genitourinary 5 1
Lung 1 5
Thyroid 2 3
Leukaemia‡ 1 2
Non-Hodgkin lymphoma 1 0
Pancreas 1 1
Meningioma 2 0
Head and neck 1 1
All deaths 374 378
Breast cancer§ 345 356
Deaths from other causes (without 
recurrence)
29 22
(Continues on next page)
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choose cyclophosphamide 100 mg/m² given orally on 
days 1–14 as an alternative to intravenous administration 
on days 1 and 8. Patients allocated to the experimental 
group received FEC (doses as for control) for four cycles 
followed by docetaxel (100 mg/m² intravenously on 
day 1 every 21 days; FEC-D) for four cycles. Docetaxel was 
infused over 1 h with dexamethasone premedication (8 mg 
orally twice a day for 3 days beginning the day before 
treatment). Patients who received docetaxel were also 
given prophylactic ciproﬂ oxacin (500 mg orally twice a day 
on days 5–14). Granulocyte colony-stimulating factor was 
used according to local practice. Clinical, haematological, 
and biochemical assessments were done before every 
cycle. Chemotherapy was delivered when neutrophil 
counts were 1·5×10⁹ cells per L or more and platelets were 
100×10⁹ per L or more. A 20% dose reduction was 
recommended for patients with grade 3 non-
haematological toxicity with treatment delay allowed until 
resolution. Discontinuation of treatment was recom-
mended if toxicity resulted in a delay of more than 3 weeks, 
or more than two dose reductions.
After chemotherapy, 5 years of tamoxifen was prescribed 
for patients whose tumours were positive for ER, 
progesterone receptor, or both. A protocol amendment in 
2005 formalised use of aromatase inhibitors as an 
alternative to tamoxifen in accordance with local policy. 
Patients with HER2-positive tumours were allowed to 
enter clinical trials assessing trastuzumab. Radiotherapy, 
which started within 4 weeks of chemotherapy 
completion, was mandatory after breast conserving 
surgery and was used after mastectomy according to local 
guidelines. 
Adverse events were assessed after every chemotherapy 
cycle and all patients were followed up every 3 months 
for 2 years post treatment. Subsequent clinical follow-up 
was as per local policy with relevant details being 
forwarded to the clinical trial units yearly or on occurrence 
of an event.
Selected centres invited all patients to participate in a 
questionnaire-based6–9 quality of life substudy.10,11 Detailed 
results and an economic analysis12 that examines costs 
incurred by the experimental regimen compared with 
the control regimen will be reported separately.
The primary endpoint of the study was invasive 
disease-free survival, deﬁ ned as time from 
randomisation to ﬁ rst invasive relapse, new primary 
breast cancer (ipsilateral or contralateral), or death from 
any cause; patients who remained alive and disease-free 
at their date of last follow-up were censored. Secondary 
endpoints were metastasis-free survival (time from 
randomisation to ﬁ rst distant relapse or death from 
breast cancer), overall survival (time from randomisation 
to death from any cause) and tolerability of the regimens 
(including compliance and acute adverse events). 
Relative dose intensity was used as a measure of 
treatment compliance, as in previous large UK 
randomised trials.13 Adverse events were graded 
HR 0·95 (95% CI 0·85–1·08)
Stratiﬁed log-rank test: p=0·44
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Figure 2: Disease-free survival (A) and overall survival (B) by treatment group
FEC-D=ﬂ uorouracil, epirubicin, and cyclophosphamide followed by docetaxel. HR=hazard ratio. Number in 
parentheses indicates events occurring after year 5. Disease-free survival events were seen in 517 of 2073 patients 
in the FEC-D group and in 539 of 2089 patients in the control group.
FEC-D 
(experimental) 
group (n=2073)
Control 
group 
(n=2089)
(Continued from previous page)
Cancer (non-breast) 8 11
Treatment toxicity¶ 6 1
Other 15 10
Vascular (cardiac) 5 3
Vascular (cerebral) 2 1
Vascular (thromboembolic) 0 2
Respiratory 1 2
Accident, suicide, alcoholism 5 2
Unknown 2 0
FEC-D=ﬂ uorouracil, epirubicin, and cyclophosphamide followed by docetaxel. 
*Includes contralateral breast cancer recurrences and new contralateral and 
ipsilateral breast second primary tumours.†Includes 12 patients in the FEC-D group 
and 11 patients in the control group who died from breast cancer without separate 
report of metastatic relapse. ‡FEC-D group: acute myeloid leukaemia; control: 
chronic myleoid leukaemia, acute lymphoblastic leukaemia. §Includes deaths 
following breast cancer recurrence. ¶Deaths occurring during chemotherapy or 
within 30 days of chemotherapy completion and without disease relapse.
Table 3: Events contributing to disease-free survival and numbers of 
distant relapses, second cancers, and deaths
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according to National Cancer Institute Common 
Toxicity Criteria14 and coded by use of the Medical 
Dictionary for Regulatory Activities (MedDRA version 
10)15 with central clinical review (by PB-L and PE) when 
needed. 
Statistical analysis 
A 5-year disease-free survival of 70% after anthracycline 
chemotherapy was predicted, with 3342 patients needed 
to detect a 5% absolute improvement (5% two-sided 
signiﬁ cance; 90% power). In January, 2003, while 
recruitment was in progress, the trial steering committee 
recommended continuation of recruitment beyond that 
target to provide adequate power to detect a smaller yet 
clinically meaningful diﬀ erence of 4%. This 
recommendation was based on external data that 
indicated improved outcome after anthracycline 
treatment.2,13 A revised sample size of 4000 patients 
(3848 plus a small allowance for dropouts) was agreed. 
1038 disease-free survival events were needed to provide 
80% power to detect an absolute diﬀ erence in 5-year 
disease-free survival of 4% (from 71% to 75%, hazard 
ratio [HR] 0·84).
For survival-related endpoints, Kaplan-Meier curves 
were plotted and treatment groups compared by use of 
the log-rank test. HRs (with 95% CIs) were obtained 
from Cox proportional hazards regression models with 
HR less than 1 favouring the experimental regimen. The 
proportionality assumption of the Cox model was tested 
with Schoenfeld residuals and found to hold. Unless 
stated otherwise, all analyses were unadjusted and 
stratiﬁ ed by centre’s choice of control regimen. The 
principal analysis includes all patients as randomised 
on an intention-to-treat (ITT) basis. Sensitivity analyses 
were done for patients receiving eight cycles of protocol 
treatment and for those receiving more than 85% 
relative dose intensity. A further sensitivity analysis 
excluding 16 unevaluable patients gave results consistent 
with the ITT analysis. A priori deﬁ ned subgroup 
analyses by choice of control regimen, ER status, and 
nodal status were undertaken. Exploratory subgroup 
analyses were done by HER2 status and by combined 
ER and HER2 status in all patients, and in node-positive 
patients only (to replicate the analyses undertaken by 
Hayes and colleagues16). No adjustment was made for 
multiple testing in the eﬃ  cacy analyses. Fixed-eﬀ ects 
published data meta- analyses of relevant adjuvant taxane 
trials and of the subgroup of trials reporting results by 
ER/HER2 subgroups were done.
Relative dose intensities were compared between 
treatment groups using a Wilcoxon rank-sum test. 
Clinically important adverse events and those that 
diﬀ ered signiﬁ cantly between treatment groups or 
which were reported with a frequency of more than 
10% are presented. Analysis of late toxicity compared 
all signs and symptoms reported more than 2 months 
after treatment end. Since the toxicity proﬁ les of FEC 
Figure 3: Sensitivity analysis hazard ratios for disease-free survival for all 
patients receiving eight cycles of chemotherapy and all patients with 
relative dose intensity more than 85%
FEC-D=ﬂ uorouracil, epirubicin, and cyclophosphamide followed by docetaxel. 
ITT=intention to treat. 
0·6
ITT (n=4162) 0·95 (0·84–1·08)
0·99 (0·86–1·14)Eight cycles (n=3357)
Relative dose intensity >85%
(n=3209)
0·97 (0·84–1·12)
Favours FEC-D Favours control
1·0
HR (95% CI) HR (95% CI)
1·5
Figure 4: Hazard ratios for disease-free survival by centre’s choice of control regimen, and patient and 
tumour characteristics
E-CMF=epirubicin followed by cyclophosphamide, methotrexate, and ﬂ uorouracil. ER=oestrogen receptor. 
FEC=ﬂ uorouracil, epirubicin, and cyclophosphamide. FEC-D=FEC followed by docetaxel. HER2=human epidermal 
growth factor receptor 2. HR=hazard ratio. *p=0·55 for heterogeneity.
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0·97 (0·79–1·20)
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0·97 (0·75–1·26)
0·85 (0·69–1·04)
1·11 (0·89–1·38)
 0·90 (0·63–1·29)
1·84 (0·84–4·05)
0·93 (0·74–1·16)
0·94 (0·81–1·09)
0·87 (0·68–1·11)
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0·91 (0·66–1·26)
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0·87 (0·72–1·05)
0·87 (0·69–1·09)
1·02 (0·87–1·19)
0·87 (0·61–1·22)
0·95 (0·85–1·08)
Centres control arm*
FEC (n=2523)
E-CMF (n=1639)
Clinical characteristics
Nodal status
    Node negative (n=835)
    1–3 positive nodes (n=1839)
    ≥4 positive nodes (n=1488)
Age (years)
    <40 (n=719)
    40–49 (n=1566)
    50–59 (n=1486)
    ≥60 (n=391)
Tumour grade
    Grade 1 (n=229)
    Grade 2 (n=1536)
    Grade 3 (n=2382)
Tumour size
    <2 cm (n=1435)
    2–5 cm (n=2330)
    >5 cm (n=392)
Biological markers
ER status
    Positive (n=2876)
    Negative (n=1286)
HER2 status
    Positive (n=847)
    Negative (n=2724)
    Unknown (n=591)
Overall
HR (95% CI) HR (95% CI)
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and E-CMF were known to diﬀ er, adverse event 
comparisons were also done by centre’s choice of 
control regimen. Where appropriate, adverse event 
data were censored 3 months before relapse. The 
proportion of patients with grade 3 or 4 toxicity in each 
treatment group was compared by use of a χ² test or 
exact test as appropriate. Quality of life data were 
analysed for patients with baseline forms completed 
before chemotherapy. Mean changes in scores from 
baseline were compared between groups by t tests. A 
signiﬁ cance level of p<0·01 allowed some adjustment 
for multiple testing of toxicity and quality of life 
endpoints. This analysis is based on a database snap-
shot frozen on May 1, 2008. All analyses were done in 
STATA 9.2. This study is registered as an Inter-
national Standard Randomised Controlled Trial, 
number ISRCTN79718493.
Role of the funding source
The trial design was approved by Cancer Research UK’s 
Clinical Trials Awards and Advisory Committee. Other 
than this, none of the funders had any role in study 
design, data collection, data analysis, data interpretation, 
or writing of the report. The corresponding author had 
full access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for 
publication.
Results 
Figure 1 shows the trial proﬁ le. Between February, 2001, 
and July, 2003, 2073 women were randomly assigned to 
the FEC-D regimen and 2089 women were assigned to 
control. Median follow-up was 62·0 months (IQR 
56·9–69·9) with complete follow-up data available for 
3191 (94%) of 3410 alive patients.
The patient population was representative of UK 
patients typically classiﬁ ed, in the early 2000s, as needing 
adjuvant chemotherapy with potential for taxane exposure 
(table 1); approximately a third of patients had ER-negative 
tumours and a quarter had HER2-positive tumours.
Eight cycles of randomised treatment were received by 
3357 (81%) patients overall (table 2), and by similar 
proportions of patients in the experimental and control 
groups. The predominant reason for discontinuation of 
therapy was toxicity (ﬁ gure 1). Median relative dose 
intensity per patient was 94·5% (IQR 85·6–99·2) for the 
experimental group and 95·9% (80·5–99·6) for the 
control group (p=0·06) in centres that used the FEC 
control regimen and 94·7% (87·1–99·4) for the 
experimental group and 96·8% (91·2–99·7) for controls 
(p<0·0001) in centres that used the E-CMF control 
regimen. 3209 patients (77%) had a relative dose intensity 
of more than 85%, which was achieved by similar 
proportions of patients in the experimental and control 
groups. 
Events related to disease-free survival were reported for 
1056 patients (table 3). Most events were related to distant 
recurrence, either as a ﬁ rst event or subsequent to further 
breast disease. No evidence was found of a diﬀ erence in 
disease-free survival between the FEC-D group and the 
control group (overall HR 0·95, 95% CI 0·85–1·08; 
stratiﬁ ed log-rank test p=0·44; ﬁ gure 2). 5-year disease-
free survival rates were 75·6% (95% CI 73·7–77·5) for the 
experimental group and 74·3% (72·3–76·2) for con trols 
(absolute diﬀ erence [experimental–control] 1·3%, –2·2 to 
4·8). Adjustment for factors known to aﬀ ect prognosis 
(ER status, nodal status, HER2 status, age, tumour grade, 
and tumour size) gave an HR of 0·93 (0·82–1·05; 
p=0·25) and sensitivity analyses showed negligible eﬀ ect 
of treatment non-adherence on the treatment group 
comparison (ﬁ gure 3).
No evidence was found of a diﬀ erence in treatment 
eﬀ ect according to a centre’s choice of control regimen 
(ﬁ gure 4). The estimated diﬀ erence in disease-free 
survival at 5 years (experimental–control) was 0·6% 
(–3·9 to 5·1) in centres that used the FEC control regimen 
and 2·5% (–3·0 to 8·0) in centres that used the E-CMF 
control regimen. No evidence of heterogeneity was seen 
between common clinical subgroups (ﬁ gure 4). In 
relation to single biological makers, there was no strong 
evidence for a diﬀ erential eﬀ ect according to ER status 
(test for interaction [adjusted] p=0·10) or HER2 status (test 
for interaction [adjusted] p=0·13). An exploratory analysis, 
replicating the one undertaken in the CALGB 9344 trial,16 
compared the putative treatment eﬀ ect according to 
Figure 5: Hazard ratios for disease-free survival by combined ER and HER2 status in (A) all patients and 
(B) node-positive patients
ER=oestrogen receptor. FEC-D=ﬂ uorouracil, epirubicin, and cyclophosphamide followed by docetaxel.
HER2=human epidermal growth factor receptor 2. HR=hazard ratio.
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combined eﬀ ects of ER and HER2 (ﬁ gure 5); results for 
patients with ER-negative and HER2-positive tumours, 
especially those who had positive lymph nodes, were 
consistent with a clinically relevant improvement in 
disease-free survival with taxane-based treatment.
Of 752 deaths, 374 were in the experimental group 
378 were in the control group (table 3). Overall survival 
did not diﬀ er between groups (ﬁ gure 2). 5-year overall 
survival rates were 82·5% (80·7–84·1) in the experimental 
group and 83·0% (81·3–84·6) in the control group. 
51 patients (experimental, n=29; control, n=22) died with 
no relapse of breast cancer.
No evidence was found to suggest a diﬀ erence in 
metastasis-free survival between experimental and 
control groups (446 vs 465 events; HR 0·96, 0·84–1·09; 
p=0·52). 5-year metastasis-free survival rates were 78·8% 
(95% CI 76·9–80·5) for the experimental group and 
77·7% (75·8–79·5) for controls.
Seven patients died during or immediately after 
treatment (table 3); ﬁ ve of these deaths were caused by 
infection (FEC-D, n=4 [one patient died during the FEC 
phase and three patients died during the docetaxel phase 
of treatment]; E-CMF control, n=1 [the patient died 
during the CMF phase of treatment]) with the other two 
deaths (both in patients assigned to FEC-D) caused by 
cerebral haemorrhage.
The proportion of patients reporting any acute grade 3 
or 4 toxicity, occurring during treatment and within 
30 days of treatment end, was signiﬁ cantly greater in 
the experimental group than in the control group 
(table 4). As expected, the toxicity proﬁ le of the experi-
mental and control groups diﬀ ered. The higher 
frequency of grade 3 or 4 infection in the experi mental 
group compared with the control group (293 [14%] 
patients vs 182 [9%] patients) was predominantly due to 
a higher infection rate in cycles ﬁ ve to eight in the 
FEC-D group in centres using FEC control (131 [11%] vs 
41 [3%]). The higher frequency of grade 3 or 4 neutropenia 
after treatment with FEC-D compared with control 
(937 [45%] vs 797 [38%]) was mainly due to higher neutro-
penia rates in the FEC-D group than in the E-CMF 
control group (392 [49%] vs 297 [37%]). The following 
late adverse events (reported more than 2 months after 
treatment end) were more frequent in the experi mental 
group than in the control group: musculo skeletal 
disorders (295 [14%] vs 211 [10%]; p<0·0001), CNS 
disorder (288 [14%] vs 93 [4%]; p<0·0001), myalgia/
arthralgia (203 [10%] vs 131 [6%]; p<0·0001), 
skin disorders (99 [5%] vs 53 [3%]; p=0·0002), oedema 
(94 [5%] vs 60 [3%]; p=0·007), and alopecia (22 [1%] vs 
7 [0·3%]; p=0·005). One case of acute myeloid leukaemia 
was reported in the experi mental group. 
Centres providing FEC control regimen Centres providing E-CMF control regimen
FEC-D (n=1254) FEC control 
(n=1262)
p value FEC-D (n=807) E-CMF control 
(n=812)
p value
Any grade 3 or 4 toxic eﬀ ect 868 (69%) 761 (60%) <0·0001 592 (73%) 513 (63%) <0·0001
Haematological
Anaemia 9 (0·7%) 6 (0·5%) 0·45* 4 (0·5%) 8 (1%) 0·39*
Febrile neutropenia 87 (7%) 25 (2%) <0·0001 59 (7%) 36 (4%) 0·01
Leucopenia 280 (22%) 224 (18%) 0·004 227 (28%) 138 (17%) <0·0001
Neutropenia 545 (44%) 500 (40%) 0·05 392 (49%) 297 (37%) <0·0001
Thrombocytopenia 8 (0·6%) 11 (0·9%) 0·65* 4 (0·5%) 16 (2%) 0·01*
Non-haematological
Alopecia 113 (9%) 117 (9%) 0·82 97 (12%) 96 (12%) 0·90
Diarrhoea 46 (4%) 23 (2%) 0·005 31 (4%) 36 (4%) 0·55
Infection 183 (15%) 86 (7%) <0·0001 110 (14%) 96 (12%) 0·28
Lethargy 275 (22%) 158 (13%) <0·0001 181 (22%) 114 (14%) <0·0001
Musculoskeletal—other† 74 (6%) 13 (1%) <0·0001 70 (9%) 18 (2%) <0·0001
Myalgia/arthralgia 60 (5%) 1 (0·1%) <0·0001* 44 (5%) 2 (0·2%) <0·0001*
Nausea/vomiting 113 (9%) 127 (10%) 0·37 86 (11%) 78 (10%) 0·48
Neuropathy 68 (5%) 4 (0·3%) <0·0001* 30 (4%) 7 (0·9%) 0·0001*
Oedema 11 (0·9%) 1 (0·1%) 0·003* 6 (0·7%) 5 (0·6%) 0·77*
Pain 8 (0·6%) 1 (0·1%) 0·02* 50 (6%) 2 (0·2%) 0·004*
Skin disorder (including nail changes) 41 (3%) 10 (0·8%) <0·0001* 26 (3%) 14 (2%) 0·05
Stomatitis (mucositis) 87 (7%) 28 (2%) <0·0001 69 (9%) 46 (6%) 0·02
E-CMF=epirubicin followed by cyclophosphamide, methotrexate, and ﬂ uorouracil. FEC=ﬂ uorouracil, epirubicin, and cyclophosphamide. FEC-D=FEC followed by docetaxel. 
Analysis of adverse events was undertaken on the safety population which included 4135 patients who received some randomised treatment. Events were coded by use of 
the Medical Dictionary for Regulatory Activities (MedDRA version 10).15 The proportion of patients with grade 3 or 4 toxicity in each treatment group was compared by use of 
a χ² test or exact test (indicated by *) as appropriate. †Excluding arthralgia and myalgia.
Table 4: Frequency of grade 3 or 4 adverse events during chemotherapy
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In 829 patients who participated in the quality of life 
substudy, deterioration in quality of life during chemo-
therapy was clinically relevant. Signiﬁ cantly greater 
impairment was seen in the experimental group than in 
the control group with respect to physical (p<0·0001), 
role (p=0·002), emotional functioning (p=0·008), social 
functioning (p=0·003), pain (p=0·001), fatigue 
(p=0·006), and global quality of life (p=0·001); however, 
there was signiﬁ cantly more nausea and vomiting in the 
control group (p=0·01).10 Diﬀ erences between groups 
diminished over 24 months and returned close to 
baseline levels. 
Discussion
This report, from the largest of the primary adjuvant 
taxane trials, does not show any overall signiﬁ cant gain 
from the addition of docetaxel every 3 weeks to standard 
anthracycline chemotherapy of similar duration. 
Additionally, the anthracycline-docetaxel sequential 
schedule was associated with a higher frequency of 
adverse events and transiently poorer quality of life than 
the non-taxane control regimen. Recruitment for the 
TACT study was spread across specialist cancer hospitals, 
university teaching hospitals, and smaller community 
general hospitals, and at its peak accrual consisted of 
approximately a quarter of the UK eligible population, 
thus supporting the applicability of the results to general 
clinical practice. The size and maturity of this trial, 
together with its completeness of follow-up, suggest that 
the results should be considered in the balance of 
worldwide evidence on the eﬀ ects of taxanes in early 
breast cancer. 
The ﬁ ndings reported here suggest a smaller eﬀ ect 
from the incorporation of docetaxel into adjuvant breast 
cancer treatment than might have been expected based 
on worldwide evidence to date.17,18 Several issues should 
be considered when interpreting a trial’s results, 
including its contemporaneous setting. When this study 
began in 2001, two chemotherapy regimens, FEC60 (ie, 
epirubicin dose 60 mg/m²) and E-CMF, were commonly 
used for early breast cancer in the UK. Since this trial 
brought together a national community of clinical 
researchers around a speciﬁ c trial question, it was 
crucial that both regimens were oﬀ ered as choice of 
control. A key feature in the study’s design was to ensure 
that the same number of cycles were delivered in each 
comparator group. Because the trial was powered for 
the overall anthracycline-taxane comparison, a choice of 
control regimen with unbiased allocation of treatment 
adds to the robustness of the results. By today’s standards 
the epirubicin dose in FEC60 might be regarded as 
suboptimum;19,20 however, in 2001, eight cycles of FEC 
with an epirubicin dose above 60 mg/m² were considered 
undeliverable to a general UK population. Although the 
dose of epirubicin has been subsequently increased,19 
the optimum dose in adjuvant therapy remains 
controversial. The results reported here suggest that 
eight cycles of FEC60 were at least as eﬀ ective as E-CMF 
(considered worldwide as a dose-intensive anthracycline 
standard regimen) when compared with FEC-D. 
Although there were early concerns about the number 
of women discontinuing therapy in both control and 
experimental groups after six cycles (the UK standard at 
the time), prompt measures, including information 
dissemination and advice, were introduced, which 
resulted in improved subsequent compliance.21 
Sensitivity analyses including only those who received 
protocol-speciﬁ ed treatment showed that the overall 
result from the ITT population was unlikely to have 
been biased by non-compliance. Finally, aromatase 
inhibitor use was slightly higher in patients in the 
control group than in those in the experimental group, 
and although the trial pre-dated routine trastuzumab 
use, 74 patients are known to have received this drug via 
the HERA trial.22 The use of anti-HER2 or aromatase 
inhibitor therapy is highly unlikely to have aﬀ ected the 
results.
Substantial heterogeneity exists between the designs 
of trials that test taxane use in early breast cancer. 
When the TACT study was designed, docetaxel given in 
3-weekly intervals was the most widely used taxane 
regimen in Europe and was standard treatment for 
Figure 6: Meta-analysis of disease-free survival for trials of taxane-based versus anthracycline-based 
adjuvant chemotherapy
A=doxorubicin. C=cyclophosphamide. D=docetaxel. dd=dose dense. F=ﬂ uorouracil. P=paclitaxel. E=epirubicin. 
M=methotrexate. HR=hazard ratio. *HR from Cochrane review.17
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metastatic disease in the UK, which justiﬁ ed its use in 
this trial. Although no trial is exactly analogous to the 
TACT study, there are other trials of similar sequential 
taxane therapy in which total chemotherapy duration is 
similar in the comparator group. The PACS 01 trial23 
included 1999 node-positive breast cancer patients and 
compared six cycles of FEC100 with three cycles of 
FEC100 followed by three cycles of docetaxel 100 mg/m². 
The results of the study showed a small but signiﬁ cant 
improvement in both disease-free and overall survival 
in favour of sequential docetaxel. In a pre-planned 
subgroup analysis, no beneﬁ t was seen in women aged 
under 50 years, an anomaly that remains unexplained. 
The GEICAM 9906 study,24 which compared six cycles 
of FEC90 with four cycles of FEC90 followed by 
paclitaxel given once a week for 8 weeks, reported a 
beneﬁ t for both disease-free and overall survival for 
paclitaxel and did not ﬁ nd the speculative age eﬀ ect 
seen in PACS 01. 
There is substantial variation between results from 
individual taxane trials.17,18 Figure 6 summarises an 
updated meta-analysis that is based on published trial 
results and those reported here. Generalisations about 
taxane beneﬁ t are diﬃ  cult to make when individual 
trials are of diﬀ erent sizes, reported at diﬀ erent stages 
of maturity, have biologically heterogeneous popu-
lations, have used one or other taxane with diﬀ erent 
schedules, and are compared with diﬀ erent 
anthracycline control regimens of often unequal 
duration. Many patients seem to gain little beneﬁ t from 
additional taxanes, especially in regard to overall 
survival. An important role for adjuvant taxanes might 
be as a sequential alternative to anthracyclines, thus 
keeping both the overall anthracycline dose and 
subsequent exposure to the associated long-term 
adverse events (such as induction of leukaemia and 
cardiotoxicity) to a minimum.
The long-term beneﬁ ts of taxanes need further 
investigation. The risk of relapse for patients with 
ER-positive disease continues for at least 15 years after 
diagnosis, partly as a consequence of eﬀ ective endocrine 
therapy. Current estimates of the eﬀ ect of adjuvant 
taxane therapy on disease outcome in patients with 
ER-positive tumours are aﬀ ected by events in early 
years and further follow-up is needed before a possible 
longer term beneﬁ t can be identiﬁ ed or excluded in this 
patient population.
In view of the molecular diversity of breast cancer, 
adjuvant taxanes might provide diﬀ erent beneﬁ ts for 
particular patient subgroups. Therefore, clinicians need 
to identify patients who would—and, just as importantly, 
who would not—obtain beneﬁ t from this treatment. In 
isolation, biological markers such as ER or HER234–36 
seem to have little predictive value in determining 
taxane responsiveness; however, more complex 
biological groupings could prove more informative. A 
retrospective subgroup analysis of 1322 node-positive 
patients in the CALGB 9344 trial16 suggested that the 
beneﬁ ts of paclitaxel occurred mainly in those with 
ER-negative or HER2-positive tumours with little or no 
gain in the largest subgroup of patients—namely, those 
with the ER-positive/HER2-negative phenotype. In a 
similar analysis in this trial, docetaxel beneﬁ t was most 
apparent in patients whose tumours were ER negative 
and HER2 positive, with other subgroups deriving lesser 
or no apparent beneﬁ t. Four trials have published results 
by ER and HER2 status (ﬁ gure 7). We postulate that 
patients with ER-positive and HER2-negative cancers 
might not gain a clinically worthwhile beneﬁ t from 
taxanes; however, long-term follow-up is needed to 
conﬁ rm this hypothesis. The pending EBCTCG 
individual patient data meta-analysis of adjuvant taxanes 
in early breast cancer provides the best opportunity for 
clariﬁ cation, especially if biological data from other 
trials can be incorporated into the analysis. The 
conﬁ rmation of such a hypothesis would have huge 
implications for treatment worldwide, through the 
reduction of treatment toxicity and improvement of 
resource use. 
Figure 7: Meta-analysis of disease-free survival for trials of taxane-based versus anthracycline-based 
adjuvant chemotherapy that reported combined ER/HER2 subgroup analyses
ER=oestrogen receptor. HER2=human epidermal growth factor receptor 2. p=0·03 heterogeneity test for 
comparison of the HRs across the four subgroups of ER/HER2 status.  
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